Neurological applications for myocardial MIBG scintigraphy

Nuclear Medicine Review

Volumn 16, Issue 1, 2013, Pages 35-41

  Cascini, Giuseppe Lucio ^a   Cuccurullo, Vincenzo ^b   Restuccia, Antonio ^a   Tamburrini, Oscar ^a   Rotondo, Antonio ^b   Mansi, Luigi ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

MIBG; Myocardium; Parkinson disease; Parkinsonism; Sympathetic innervation

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; DOPAMINE F 18; NEUROLEPTIC AGENT; TRACER; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; CARDIAC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DOPAMINERGIC ACTIVITY; DRUG UPTAKE; HEART INNERVATION; HUMAN; NONHUMAN; NORADRENERGIC SYSTEM; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SYMPATHETIC INNERVATION;

3-IODOBENZYLGUANIDINE; HEART; HUMANS; MYOCARDIAL PERFUSION IMAGING; PARKINSON DISEASE; SENSITIVITY AND SPECIFICITY; SYMPATHETIC NERVOUS SYSTEM;

EID: 84879649534     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: 10.5603/NMR.2013.0007     Document Type: Review

References (58)

1. Bengel FM, Schwaiger M. Assessment of cardiac sympathetic neuronal function using PET imaging. J Nucl Cardiol 2004; 11: 603-616. (Pubitemid 39341805)
2. Sisson JC, Wieland DM. Radiolabeled meta-iodobenzylguanidine: Pharmacology and clinical studies. Am J Physiol Imaging 1986; 1: 96-103. (Pubitemid 17188385)
3. Somsen GA, Verberne HJ, Fleury E, Righetti A. Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: implications for clinical studies. J Nucl Cardiol 2004; 11: 126-133. (Pubitemid 38949906)
4. Jacobson AF, Senior R, Cerqueira MD et al. ADMIRE-HF Investigators. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010; 55: 2212-2221.
5. Patel AD, Iskandrian AE. MIBG imaging. J Nucl Cardiol 2002; 9: 75-94. (Pubitemid 34196234)
6. Agostini D, Carrio I, Verberne HJ. How to use myocardial 123I-MIBG scintigraphy in chronic heart failure. Eur J Nucl Med Mol Imaging 2009; 36: 555-559.
7. Goldstein DS, Holmes C, Cannon RO 3rd, Eisenhofer G, Kopin IJ. Sympathetic cardioneuropathy in dysautonomias. N Engl J Med 1997; 336: 696-702. (Pubitemid 27102684)
8. Amino T, Orimo S, Itoh Y, Takahashi A, Uchihara T, Mizusawa H. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol 2005; 15: 29-34. (Pubitemid 40224064)
9. Orimo S, Takahashi A, Uchihara T, Mori F, Kakita A, Wakabayashi K, Takahashi H. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson''s disease. Brain Pathol 2007; 17: 24-30.
10. Arabia G, Novellino F, Morelli M et al. Mixed tremors with integrity of nigrostriatal system: a clinical and DAT-SPECT follow-up study. Mov Disord 2010; 25: 662-664.
11. Novellino F, Arabia G, Bagnato A et al. Combined use of DAT-SPECT and cardiac MIBG scintigraphy in mixed tremors. Mov Disord 2009 15; 24: 2242-2248.
12. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. Arch Neurol 1964; 10: 333-359.
13. Rebeiz JJ, Kolodny EH, Richardson EP. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968; 18: 20-33.
14. Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003; 54: S15-S19. (Pubitemid 36760148)
15. Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 1969; 32: 28-34.
16. Gilman S, Wenning GK, Low PA. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670-676.
17. Goldstein DS, Sewell L, Holmes C. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 2002; 58: 1247-1255. (Pubitemid 34411870)
18. Goldstein DS, Sewell L, Holmes C. Association of anosmia with autonomic failure in Parkinson disease. Neurology 2010; 74: 245-251.
19. Kashihara K, Imamura T, Shinya T. Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson's disease. Parkinsonism Relat Disord 2010; 16: 252-255.
20. Goldstein DS, Holmes C, Bentho O et al. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 2008; 14: 600-607.
21. Paglionico S, Labate A, Salsone M et al. Involvement of cardiac sympathetic nerve endings in a patient with idiopathic RBD and intact nigrostriatal pathway. Parkinsonism Relat Disord 2009; 15: 789-791.
22. Miyamoto T, Miyamoto M, Inoue Y, Usui Y, Suzuki K, Hirata K. Reduced cardiac 123I-MIBGscintigraphy in idiopathic REM sleep behavior disorder. Neurology 2006; 67: 2236-2238. (Pubitemid 46035486)
23. Yoshita M, Taki J, Yokoyama K et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 2006; 66: 1850-1854. (Pubitemid 44049815)
24. Novellino F, Bagnato A, Salsone M et al. Myocardial (123)I-MIBG scintigraphy for differentiation of Lewy bodies disease from FTD. Neurobiol Aging 2010; 31: 1903-1911.
25. Goldstein DS, Sewell L, Sharabi Y. Autonomic dysfunction in PD: a window to early detection? J Neurol Sci. 2011; 310: 118-122.
26. Morelli M, Arabia G, Salsone M et al. Accuracy of magnetic resonance parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease. Mov Disord 2011; 26: 527-533.
27. Cerasa A, Morelli M, Augimeri A et al. Prefrontal thickening in PD with levodopa-induced dyskinesias: New evidence from cortical thickness measurement. Parkinsonism Relat Disord 2012 Jun. [Epub ahead of print] PubMed PMID: 22742954.
28. Cerasa A, Pugliese P, Messina D et al. Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task. Mov Disord 2012; 27: 364-371.
29. Mansi L, Ciarmiello A, Cuccurullo V. PET/MRI and the revolution of the third eye. Eur J Nucl Med Mol Imaging 2012; 39: 1519-1524.
30. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998; 155: 60-67. (Pubitemid 28141060)
31. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. 123I-meta- iodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67: 189-194. (Pubitemid 29326950)
32. Watanabe H, Ieda T, Katayama T, Takeda A, Aiba I, Doyu M. Cardiac 123I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 70: 781-783. (Pubitemid 32554209)
33. Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 2005; 109: 583-588. (Pubitemid 40974147)
34. Amino T, Orimo S, Itoh Y, Takahashi A, Uchihara T, Mizusawa H. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol 2005; 15: 29-34. (Pubitemid 40224064)
35. Nakajima K, Yoshita M, Matsuo S, Taki J, Kinuya S. Iodine-123-MIBG sympathetic imaging in Lewy body diseases and related movement disorders. Q J Nucl Med Mol Imaging 2008; 52: 378-387.
36. Rascol O, Schelosky L. 123I-Metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Mov Disord 2009; 24: 732-741.
37. Treglia G, Cason E. Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with Lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging 2012; 22: 111-117.
38. Hishikawa N, Hashizume Y, Yoshida M, Sobue G. Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol 2003; 105: 341-350. (Pubitemid 36798828)
39. Jost WH, Del Tredici K, Landvogt C, Braune S. Importance of 123I-metaiodobenzylguanidine scintigraphy/single photon emission computed tomography for diagnosis and differential diagnostics of Parkinson syndromes. Neurodegener Dis 2010; 7: 341-347.
40. Treglia G, Cason E, Gabellini A, Giordano A, Fagioli G. Recent developments in innervation imaging using iodine-123-metaiodobenzylguanidine scintigraphy in Lewy body diseases. Neurol Sci 2010; 31: 417-422.
41. Yamashina S, Yamazaki J Neuronal imaging using SPECT. Eur J Nucl Med Mol Imaging 2007; 34: 939-950. (Pubitemid 46798959)
42. Treglia G, Cason E, Stefanelli A et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res. 2012; 22: 43-55.
43. Orimo S, Suzuki M, Inaba A, Mizusawa H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord 2012; 18: 494-500.
44. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 2001; 11: 351-355. (Pubitemid 34461714)
45. Köllensperger M, Seppi K, Liener C, Boesch S, Heute D, Mair KJ. Diffusion weighted imaging best discriminates PD from MSA-P: a comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord 2007; 22: 1771-1776. (Pubitemid 47597601)
46. Fröhlich I, Pilloy W, Vaillant M, Diederich NJ. Myocardial MIBG scintigraphy: a useful clinical tool? A retrospective study in 50 parkinsonian patients. Neurol Sci 2010; 31: 403-406.
47. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2005; 76: 249-251. (Pubitemid 40143717)
48. Spiegel J, Hellwig D, Farmakis G et al. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. Mov Disord 2007; 22: 1004-1008. (Pubitemid 46999298)
49. Orimo S, Kanazawa T, Nakamura A, Uchihara T, Mori F, Kakita A. Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol 2007; 113: 81-86. (Pubitemid 44782932)
50. King AE, Mintz J, Royall DR. Meta-analysis of (123) I-MIBG cardiac scintigraphy for the diagnosis of Lewy body- related disorders. Mov Disord 2011; 26: 1218-1224.
51. Salsone M, Bagnato A, Novellino F et al. Cardiac MIBG scintigraphy in primary progressive freezing gait. Parkinsonism Relat Disord 2009; 15: 365-369.
52. Kyuma M, Nakata T, Hashimoto A, Nagao K, Sasao H, Takahashi T. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and non cardiac disorders in patients with heart failure. J Nucl Med 2004; 45: 155-163. (Pubitemid 47628373)
53. Gazzaruso C, Coppola A, Montalcini T et al. Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus. Endocrine 2012; 41: 89-95.
54. Quattrone A, Bagnato A, Annesi G et al. Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson's disease. Mov Disord 2008; 23: 21-27. (Pubitemid 351281213)
55. Cuccurullo V, Cascini G, Rossi A, Tamburrini O, Rotondo A, Mansi L. Pathophysiological premises to radiotracers for bone metastases. Q J Nucl Med Mol Imaging 2011; 55: 353-373.
56. Mansi L, Moncayo R, Cuccurullo V, Dottorini ME, Rambaldi PF. Nuclear medicine in diagnosis, staging and follow-up of thyroid cancer. Q J Nucl Med Mol Imaging 2004; 48: 82-95. (Pubitemid 39248297)
57. Cuccurullo V, Mansi L. Toward tailored medicine (and beyond): the phaeochromocytoma and paraganglioma model. Eur J Nucl Med Mol Imaging 2012; 39: 1262-1265.
58. Teresińska A. Metaiodobenzylguanidine scintigraphy of cardiac sympathetic innervations. Nuclear Medicine Review 2012; 15: 61-70.